Acquired factor XI deficiency and therapeutic plasma exchange

2017 ◽  
Vol 33 (3) ◽  
pp. 427-430 ◽  
Author(s):  
Geoffrey D. Wool ◽  
Angela Treml ◽  
Jonathan L. Miller
Keyword(s):  
Plasma Exchange ◽  
Therapeutic Plasma Exchange ◽  
Factor Xi ◽  
Factor Xi Deficiency

Therapeutic plasma exchange for perioperative management of patients with congenital factor XI deficiency

2017 ◽  
Vol 32 (6) ◽  
pp. 429-436 ◽  
Author(s):  
Mohamed S. Alsammak ◽  
Aneel A. Ashrani ◽  
Jeffrey L. Winters ◽  
Rajiv K. Pruthi
Keyword(s):  
Plasma Exchange ◽  
Perioperative Management ◽  
Therapeutic Plasma Exchange ◽  
Factor Xi ◽  
Factor Xi Deficiency ◽  
Congenital Factor

scholarly journals Management of a Patient with Factor XI Deficiency in Total Hip Joint Replacement by Plasma Exchange Transfusion

1995 ◽  
Vol 6 (1) ◽  
pp. 22-26 ◽  
Author(s):  
Yoko TAKAHASHI ◽  
Morio ARAI ◽  
Kazuhide KAWADA ◽  
Takeshi HAGIWARA ◽  
Kagehiro AMANO ◽  
...  
Keyword(s):  
Plasma Exchange ◽  
Hip Joint ◽  
Joint Replacement ◽  
Exchange Transfusion ◽  
Factor Xi ◽  
Hip Joint Replacement ◽  
Factor Xi Deficiency ◽  
Total Hip

scholarly journals Factor XI Kinetics after Plasma Exchange in Severe Factor XI Deficiency

1986 ◽  
Vol 16 (1) ◽  
pp. 51-56
Author(s):  
I.R.O. Nováková ◽  
C.A.M. van Ginneken ◽  
H.W. Verbruggen ◽  
C. Haanen
Keyword(s):  
Plasma Exchange ◽  
Factor Xi ◽  
Factor Xi Deficiency

Acquired Factor XI Inhibitors in Two Patients with Hereditary Factor XI Deficiency

1984 ◽  
Vol 51 (03) ◽  
pp. 371-375 ◽  
Author(s):  
Kangathevy Morgan ◽  
Sandra Schiffman ◽  
Donald Feinstein
Keyword(s):  
Protein A ◽  
Lambda Light Chain ◽  
Factor Xi ◽  
Spontaneous Bleeding ◽  
Factor Xi Deficiency ◽  
Hereditary Factor ◽  
Coagulation Mechanism ◽  
Factor Xia ◽  
Polyclonal Igg ◽  
Glass Surfaces

SummaryTwo patients with hereditary factor XI deficiency developed inhibitors following plasma transfusions. Neither had severe spontaneous bleeding. The patients’ plasmas neutralized both factor XI in plasma, purified factor XI, and purified factor XIa. The inhibitor in both patients’ plasmas adsorbed to Protein A- Sepharose. The inhibitors eluted from Protein A-Sepharose were partially neutralized by kappa and lambda light chain antisera indicating that they were polyclonal IgG antibodies. Both inhibitors markedly decreased adsorption of factor XI to glass surfaces. The cleavage of factor XI by trypsin was unaffected by the inhibitors. The lack of severe spontaneous bleeding in both of these patients strongly suggests that an alternate coagulation mechanism bypassing factor XI must compensate for this severe defect.

Therapeutic Plasma Exchange Application in Children Requires Individual Decision

2020 ◽  
Author(s):  
Gürkan Atay ◽  
Demet Demirkol
Keyword(s):  
Plasma Exchange ◽  
Vascular Access ◽  
Pediatric Patients ◽  
Demyelinating Disease ◽  
Pediatric Intensive Care ◽  
Therapeutic Plasma Exchange ◽  
Transplantation Rejection ◽  
Access Problems ◽  
Uremic Syndrome

AbstractTherapeutic plasma exchange (TPE) is a treatment administered with the aim of removing a pathogenic material or compound causing morbidity in a variety of neurologic, hematologic, renal, and autoimmune diseases. In this study, we aimed to assess the indications, efficacy, reliability, complications, and treatment response of pediatric patients for TPE. This retrospective study analyzed data from 39 patients aged from 0 to 18 years who underwent a total of 172 TPE sessions from January 2015 to April 2018 in a tertiary pediatric intensive care unit. Indications for TPE were, in order of frequency, macrophage activation syndrome (28.2%, n = 11), renal transplantation rejection (15.4%, n = 6), liver failure (15.4%, n = 6), Guillain–Barre's syndrome (15%, n = 6), hemolytic uremic syndrome (7.7%, n = 3), acute demyelinating disease (7.7%, n = 3), septic shock (5.1%, n = 2), and intoxication (5.1%, n = 2). No patient had any adverse event related to the TPE during the procedure. The TPE session was ended prematurely in one patient due to insufficient vascular access and lack of blood flow (2.6%). In the long term, thrombosis due to the indwelling central catheter occurred (5.1%, n = 2). TPE appears to be an effective first-stage or supplementary treatment in a variety of diseases, may be safely used in pediatric patients, and there are significant findings that its area of use will increase. In experienced hands and when assessed carefully, it appears that the rate of adverse reactions and vascular access problems may be low enough to be negligible.

Therapeutic plasma exchange in intensive care and intensive nephrology

2018 ◽  
Vol 20 (4) ◽  
pp. 394-403
Author(s):  
M. S. Vetsheva ◽  
◽  
K.E Loss . ◽  
O.L. Podkorytova ◽  
E.V. Lebedkov ◽  
...  
Keyword(s):  
Intensive Care ◽  
Plasma Exchange ◽  
Therapeutic Plasma Exchange

Molecular analysis in 12 factor XI deficiency patients from China: Identification of three novel splicing mutations

2020 ◽  
Vol 192 ◽  
pp. 100-102
Author(s):  
Donglei Zhang ◽  
Xian Zhang ◽  
Boyang Sun ◽  
Huiyuan Li ◽  
Feng Xue ◽  
...  
Keyword(s):  
Molecular Analysis ◽  
Factor Xi ◽  
Factor Xi Deficiency ◽  
Splicing Mutations
Sign in / Sign up

Export Citation Format

Share Document